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Subgroup analyses play an important role in the interpre-
tation of clinical trials. Consistency of a treatment effect
across different demographic and baseline characteristics is
of the greatest importance, as an overall positive result may
not translate to be of beneﬁt in all subgroups. The most
important subgroups, such as those categorized by sex, age,
diabetes status, and prior myocardial infarction (MI), are
usually reported in the primary publication, followed by
a host of other publications, with only the imagination and
academic stamina limiting the number of possible analyses.
See page 1048
But subgroup analyses are fraught with pitfalls (1,2).
Both false positive (type 1) and false-negative (type 2) errors
are more likely in subgroup analyses, the former due to
multiple testing and the latter due to small sample size. The
problem with subgroup analyses was memorably high-
lighted 25 years ago when the ISIS-2 (International Study
of Infarct Survival-2) trial investigators showed that aspirin
therapy in the treatment of suspected MI appeared to be
harmful in the subgroup born under the astrological sign of
Gemini or Libra, although it was beneﬁcial in lowering
mortality and reducing recurrent MIs in the overall study
(3). No such astrological effect was seen with streptokinase.
More recently, a subgroup analysis of the ATHENA (A
Placebo-Controlled, Double Blind, Parallel Arm Trial to
Assess the Efﬁcacy of Dronedarone 400 mg bid for the
Prevention of Cardiovascular Hospitalization or Death
from any Cause in Patients with Atrial Fibrillation/Atrial
Flutter) trial suggested a beneﬁt in patients with permanent
atrial ﬁbrillation (4). Subsequently, however, the PALLAS*Editorials published in the Journal of the American College of Cardiology reﬂect the
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to disclose.(Permanent Atrial Fibrillation Outcome Study Using
Dronedarone on Top of Standard Therapy) trial (5) not
only failed to show any beneﬁt, but was prematurely
stopped due to a statistically signiﬁcant increase in mor-
tality, stroke, and heart failure, highlighting the potential
danger of subgroup analyses inﬂuencing clinical care and
forming the basis of phase 3 studies.
How, then, should we approach subgroup analyses, par-
ticularly when one subgroup is at odds with the overall
ﬁndings of the study? Beyond a hefty grain of salt, certain
subgroup analyses are more believable. The larger the
subgroup, the more believable the result; indeed, we should
be looking at the power of the subgroup itself. A rule of
thumb is to limit subgroup analyses to those that maintain
at least 40% to 50% power for the endpoint of interest (2). In
a study with 90% power, this rule would preclude analyzing
subsets comprising fewer than 30% of the original cohort.
Additional questions include whether the analysis was pre-
deﬁned, whether a formal test of interaction is signiﬁcant,
and whether there is biological plausibility for the diver-
gent ﬁndings. And ﬁnally, even if all these conditions are
met, subgroup analyses should be viewed as hypothesis-
generating and not overinterpreted.
It is with these caveats and limitations in mind that we
should examine the subgroup analysis by Whellan et al. (6)
from the TRACER (Thrombin Receptor Antagonist for
Clinical Event Reduction in Acute Coronary Syndrome)
trial published in this issue of the Journal. The TRACER
trial (7) was a large (n ¼ 12,944) phase 3 study of vora-
paxar in acute coronary syndrome. Vorapaxar, a protease-
activated-receptor 1 antagonist, inhibits the activation of
platelets by thrombin. Thrombin is considered the most
potent platelet agonist. Vorapaxar showed promise in phase
2 trials in patients with stable percutaneous coronary inter-
vention and acute coronary syndromes. Importantly, in the
phase 2 trials (8,9), there was no increased bleeding as
assessed by the Thrombolysis In Myocardial Infarction
(TIMI) bleeding score, despite concomitant dual antiplatelet
therapy in the majority of patients. Vorapaxar was therefore
touted as a potential blockbuster with anti-ischemic effects,
but no increase in bleeding. Two large phase 3 trials were
subsequently carried out, the TRACER trial (8) in patients
with acute coronary syndrome and the TRA 2P–TIMI 50
(Thrombin Receptor Antagonist in Secondary Prevention
of Atherothrombotic Ischemic Events–Thrombolysis In
Myocardial Infarction 50) trial (10) in patients with prior
MI, ischemic stroke, or peripheral arterial disease.
The TRACER trial failed to meet its primary quadruple
endpoint (cardiovascular death, MI, stroke, or ischemia-
driven revascularization or hospitalization), but did meet
the secondary triple endpoint of cardiovascular death, MI,
or stroke with a hazard ratio (HR) of 0.89 (p ¼ 0.02). Most
importantly, in divergence with the phase 2 data, there was
a signiﬁcant increase in major bleeding, including intracra-
nial hemorrhage, which was increased from 0.2% in the
placebo group to 1.1% in the vorapaxar group (HR: 3.39).
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1,312 patients from the trial who underwent coronary artery
bypass graft (CABG) surgery during the index hospitaliza-
tion and showed a 45% reduction in the primary quadruple
endpoint for the TRACER trial. Most important, there was
no signiﬁcant increase in major CABG-related bleeding.
These ﬁndings (part of a pre-speciﬁed subgroup analysis)
differ signiﬁcantly from the non-CABG group, with a p
value for interaction of 0.012.
Based on the relatively small number of patients in the
CABG subgroup, the skeptic would be inclined to dismiss
the ﬁndings, despite the signiﬁcant p value for interaction,
as this subgroup appears a priori to be underpowered, with
only 10.8% of the study population. Even the marked
beneﬁt (seen with an HR of 0.55) should be viewed with
caution. Indeed, to be statistically signiﬁcant, effects in
small-sized subgroups have to be of greater magnitude (2).
Is there biological plausibility in the results? Thrombin
generation is increased during surgery in general and on-
pump bypass surgery in particular. At the site of wounds,
such thrombin generation is beneﬁcial and necessary for
hemostasis, but when there is systemic generation of
thrombin, such as that during bypass, a host of coagulation
disorders may ensue, with both increased bleeding and
thrombosis (11). It is therefore plausible that in the setting
of CABG surgery, vorapaxar would reduce thrombin-related
platelet activation and reduce ischemic events, which in
turn may reduce perioperative MIs and thrombotic graft
failure.
The most important ﬁnding of the CABG subgroup
analysis was not, however, that it met the primary endpoint
of the TRACER trial. After all, the main trial was stopped
prematurely, showed a trend toward a reduction in the
primary endpoint with a p value of 0.07, and met the similar
secondary composite endpoint, consistent with an anti-
ischemic effect. An anti-ischemic effect was also shown in
the even larger trial, the TRA 2P–TIMI 50 trial, in patients
post-MI. Rather it is the lack of major CABG-related
bleeding and a lower, albeit still increased rate over
placebo of 2-year TIMI major bleeding that is remarkable.
One possibility is of a type II error (false negative) as the
CABG subgroup was not powered for this important safety
endpoint. A more intriguing possibility is that the CABG
subgroup had a lower risk of bleeding due to the expectedly
lower use of clopidogrel in this group. At discharge, clopi-
dogrel use in the patients undergoing CABG was only 18%
versus 84% in the non-CABG group. Clopidogrel was also
held prior to CABG, with only 39% receiving the drug
within 5 days of surgery, and probably a smaller percentage
closer to surgery.
Withholding concomitant clopidogrel treatment, how-
ever, is unlikely to prevent the most dreaded risk of treat-
ment with vorapaxar, namely intracranial hemorrhage in all
patients. In the TRA 2P–TIMI 50 trial, there was a marked
increase in intracranial hemorrhage in subjects with a history
of stroke, leading the data and safety monitoring board todiscontinue study treatment in this group 2 years into the
study. This group, as with the CABG subgroup in the
TRACER trial, had a low use of thienopyridines (mostly
clopidogrel) at 24%. It would appear that with vorapaxar,
intracranial bleeding is also dependent on the patient’s
underlying substrate. Thrombin generation, which is trig-
gered by release of anionic phospholipids in brain injury,
may be particularly important in preventing intracranial
hemorrhage.
Is there a second act in store for vorapaxar, once consid-
ered a potential blockbuster? Is there a future for the concept
of protease-activated receptor 1 inhibition, whether in a
surgical population or in a wider acute coronary syndrome
or percutaneous coronary intervention population? Many
uncertainties remain, including the correct dose of the drug,
either as monotherapy, in addition to aspirin or in addition
to dual antiplatelet therapy. Interestingly in the phase
2 study of vorapaxar, both the 1 mg and 2.5 mg maintenance
doses led to at least 80% inhibition of thrombin receptor
agonist peptide (TRAP)-induced platelet inhibition in
100% of patients, both at 30 and 60 days (9). Based on the
phase 2 data, the 2.5 mg dose was chosen for the phase
3 program in anticipation that major bleeding would not
be increased, an expectation which was not conﬁrmed. The
phase 2 program also indicated that the drugwould not lead to
increased bleeding, even in the presence of dual antiplatelet
therapy. Given the clear ﬁnding of increased bleeding in the
phase 3 program, thereby changing the anticipated beneﬁt/
risk ratio for the drug, the possibility of using the drug in the
absence of a P2Y12 blocker is intriguing.
Decades after the introduction of aspirin into routine
use, and more than 15 years after the availability of clopi-
dogrel, we are still deﬁning the proper dose and use of
these important antiplatelet drugs. Vorapaxar is presently
undergoing evaluation by the Food and Drug Administra-
tion for the treatment of patients with a history of prior
MI and no prior stroke and transient ischemic attack (12).
Given the issues of bleeding associated with the drug, even
if approved, its proper use will entail a difﬁcult task of
identifying the patient in whom the beneﬁt outweighs the
risk. The study by Whellan et al. (6) adds an interesting
hypothesis to the inevitable debate.
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